BridgeMD
New treatment option for UTUC
Official title POST URS Chemotherapy Instillation
ClinicalTrials.gov ID: NCT06167057
What this study is testing
What is Mitomycin/Gemcitabine?
Mitomycin/Gemcitabine is an investigational medicine, being studied as a potential treatment for utuc.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this study is to evaluate the safety and oncological outcomes of single chemotherapy bladder instillation following endoscopic treatment for UTUC in UTUC suspected patients .The main aim is to determine the efficacy of a single, post URS, chemotherapy bladder instillation to reduce IVR. Participants will be given single chemotherapy bladder instillation within 24h following ureteroscopy and will follow routine follow-up for IVR which will include white light cystoscopy ;patients with suspected IVR (based on either imaging or cystoscopy) will undergo TURBT.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Radiographic and/or cytological suspicion for UTUC
- Planned endoscopic procedure for treatment / diagnosis of UTUC
- Patients with bladder cancer history are eligible if meeting both following criteria: No recurrence within the last two years Are not on active...
- Patients with history of UTUC are eligible if last endoscopic treatment or RNU was \>1 year prior to enrollment
- Age ≥ 18 years
You likely can't join if
- people who have had bladder / prostate radiotherapy
- people with bladder cancer history on active bladder irrigation protocols or with active disease within two years prior to enrollment
- people with previously treated UTUC within one year prior to enrollment
- people with metastatic disease
See the full eligibility criteria
- Radiographic and/or cytological suspicion for UTUC
- Planned endoscopic procedure for treatment / diagnosis of UTUC
- Patients with bladder cancer history are eligible if meeting both following criteria: No recurrence within the last two years Are not on active bladder irrigation protocol
- Patients with history of UTUC are eligible if last endoscopic treatment or RNU was \>1 year prior to enrollment
- Age ≥ 18 years
- Performance status ECOG 0-2
- people who have had bladder / prostate radiotherapy
- people with bladder cancer history on active bladder irrigation protocols or with active disease within two years prior to enrollment
- people with previously treated UTUC within one year prior to enrollment
- people with metastatic disease
The study team makes the final eligibility decision.
Where it's taking place
- Ashdod, Israel
- Beersheba, Israel
- Be’er Ya‘aqov, Israel
- Haifa, Israel
- Petah Tikva, Israel
- Rehovot, Israel
- Safed, Israel
- Tel Aviv, Israel
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ashdod, Israel; Beersheba, Israel; Be’er Ya‘aqov, Israel; Haifa, Israel; Petah Tikva, Israel; Rehovot, Israel and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.